Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by high disease burden in some countries, as well as delays in reaching mortality targets due to the long natural history of disease progression to liver cirrhosis and hepatocellular carcinoma.
Shooting Up: infections and other injecting-related harms among people who inject drugs in the UK, 2023 update
Download
This report describes the extent of infections and injecting-related harms among people who inject drugs (PWID) in the United Kingdom. This report is an update issued in March 2023 and includes the most recent data, which covers the period up to the end of 2021.
